Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Current clinical practice… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies

Artikel i vetenskaplig tidskrift
Författare I. K. Na
M. Buckland
C. Agostini
J. D. M. Edgar
Vanda Friman
M. Michallet
S. Sanchez-Ramon
C. Scheibenbogen
I. Quinti
Publicerad i European Journal of Haematology
Volym 102
Nummer/häfte 6
Sidor 447-456
ISSN 0902-4441
Publiceringsår 2019
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 447-456
Språk en
Länkar dx.doi.org/10.1111/ejh.13223
Ämnesord chronic lymphocytic leukemia, hematological disorders, immunoglobulins, infection, international, chronic lymphocytic-leukemia, immunoglobulin replacement therapy, multiple-myeloma, intravenous immunoglobulin, antibody deficiency, subcutaneous immunoglobulin, immune-deficiency, guidelines, rituximab, hypogammaglobulinemia, Hematology, apel h, 1994, british journal of haematology, v88, p209, apel hm, 1994, lancet, v343, p1059
Ämneskategorier Hematologi, Cancer och onkologi

Sammanfattning

Objective Despite long-standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B-cell lymphoproliferative diseases are limited. Here, we examine the correlation between approved IgRT indications, treatment recommendations, and clinical practice in SID. Methods An international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted. Results Serum immunoglobulin was measured in 83% of patients with multiple myeloma, 76% with chronic lymphocytic leukemia, and 69% with non-Hodgkin lymphoma. Most physicians (85%) prescribed IgRT after >= 2 severe infections. In Italy, Germany, Spain, and the United States, immunoglobulin use was above average in patients with hypogammaglobulinemia, while in the UK considerably fewer patients received IgRT. The use of subcutaneous immunoglobulin was highest in France (34%) and lowest in Spain (19%). Immunologists measured specific antibody responses, performed test immunization, implemented IgRT, and used subcutaneous immunoglobulin more frequently than physicians overall. Conclusions The management of SID in hematological malignancies varied regionally. Clinical practice did not reflect treatment guidelines, highlighting the need for robust clinical studies on IgRT in this population and harmonization between countries and disciplines.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?